论文部分内容阅读
目的:观察氨氯地平贝那普利复方制剂治疗尿毒症肾性高血压的疗效。方法:回顾性分析2018年7月至2019年12月山西汾西矿业（集团）有限责任公司职工总医院收治的尿毒症肾性高血压患者60例的临床资料，根据治疗方案不同分为贝那普利治疗（对照组）和氨氯地平贝那普利复方制剂治疗（观察组），每组30例。比较两组治疗前、治疗2周后血压值、24 h平均舒张压/收缩压变异性（24 h DBPV、24 h SBPV）、血尿素氮（BUN）、血肌酐（Scr）及用药安全性。结果:治疗前，两组血压及血压变异性比较，差异均无统计学意义（n t=0.019、0.322、0.106、0.027，均n P>0.05）；治疗2周后，两组收缩压、舒张压及24 h SBPV、24 h DBPV均降低，且观察组均低于对照组，差异均有统计学意义［（132.38±9.16）mmHg比（142.27±9.17）mmHg，（80.17±5.05）mmHg比（85.67±6.49）mmHg，（9.23±1.45）mmHg比（11.77±1.68）mmHg，（7.02±0.69）mmHg比（8.79±0.81）mmHg，n t=4.179、3.663、9.111、6.269，均n P0.05）。两组不良反应发生率比较，差异无统计学意义［26.66%（8/30）比20.00% （6/30），χn 2=0.373，n P>0.05］。n 结论:氨氯地平贝那普利复合制剂对于尿毒症肾性高血压患者的降压作用更明显，能降低血压变异性，临床安全性高。“,”Objective:To investigate the efficacy of amlodipine and benazepril in the treatment of renal hypertension in uremia.Methods:The clinical data of 60 uremic patients with renal hypertension who received treatment in General Staff Hospital of Shanxi Fenxi Mining (Group) Co., Ltd., from July 2018 to December 2019 were retrospectively analyzed. According to different treatment methods, these patients were divided into a control group (benazepril treatment) and an observation group (benazepril/amlodipine compound preparation treatment), with 30 patients in each group. Blood pressure before and 24 hours after treatment, 24-hour diastolic blood pressure variability, 24-hour systolic blood pressure variability, blood urea nitrogen, serum creatinine and medication safety were compared between the control and observation groups.Results:Before treatment, there were no significant differences in blood pressure and blood pressure variability between the control and observation groups (n t = 0.019, 0.322, 0.106, 0.027, alln P > 0.05). After 2 weeks of treatment, systolic blood pressure, diastolic blood pressure, 24-hour diastolic blood pressure variability and 24-hour systolic blood pressure variability in the observation group were significantly decreased compared with the control group [(132.38 ± 9.16) mmHg n vs. (142.27 ± 9.17) mmHg, (80.17 ± 5.05) mmHg n vs. (85.67 ± 6.49) mmHg, (9.23 ± 1.45) mmHg n vs. (11.77 ± 1.68) mmHg, (7.02 ± 0.69) mmHg n vs. (8.79 ± 0.81) mmHg, n t = 4.179, 3.663, 9.111, 6.269, all n P 0.05). No significant difference in the incidence of adverse reactions was observed between the two groups [26.66% (8/30) n vs. 20.00% (6/30), χn 2 = 0.373, n P > 0.05].n Conclusion:Amlodipine and benazepril compound preparation exhibits more obvious antihypertensive effect in uremic patients with renal hypertension than benazepril treatment, can reduce blood pressure variability, and is highly safe in the clinic。